相关临床试验
0
0 进行中
药物批准
4
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- The U.S. Economic Development Administration has awarded $15.97 million to launch the End-to-End Commercialization Project led by Civica, Inc., with support from Phlow Corp. and Occam Systems. - The project will establish an integrated domestic pathway from key starting materials through API manufacturing, finished dose formulation, FDA approval, and commercial delivery to patients. - Four essential sterile injectable medicines—ketamine, midazolam, norepinephrine, and succinylcholine—will be the initial focus, targeting emergency, anesthesia, and critical care settings. - The initiative builds on over $1.7 billion in prior investments and involves more than 55 Alliance for Building Better Medicine partners spanning industry, academia, government, and workforce development.
- Virginia lawmakers unanimously approved economic development packages worth over $10 million each for AstraZeneca's multibillion-dollar manufacturing plant in Albemarle County and Eli Lilly's facility in Goochland County. - The AstraZeneca project represents part of a $50 billion five-year investment plan and will be the company's largest global manufacturing investment, strategically located near the University of Virginia's Manning Institute of Biotechnology. - Both pharmaceutical giants are expanding domestic manufacturing capacity amid potential tariff threats, with Eli Lilly committing $50 billion over five years to double its U.S. manufacturing investments. - The Virginia facilities will strengthen a pharmaceutical manufacturing corridor extending from the Shenandoah Valley to Richmond, positioning the state as a major center for advanced pharmaceutical production.
